Ticker
ACAD

Price
19.83
Stock movement down
-0.08 (-0.40%)
Company name
ACADIA Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
3.21B
Ent verdi
3.23B
Pris/omsetning
6.28
Pris/bok
7.54
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-15.29%
3 års avkastning
-21.93%
5 års avkastning
-8.11%
10 års avkastning
12.42%
Sist oppdatert: 2023-02-03

UTBYTTE

ACAD betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning6.28
Pris til bok7.54
EV i forhold til salg6.32

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall161.93M
EPS (TTM)-1.34
FCF per aksje (TTM)-0.70

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)511.50M
Bruttofortjeneste (TTM)501.19M
Driftsinntekter (TTM)-222.19M
Netto inntekt (TTM)-217.34M
EPS (TTM)-1.34
EPS (1 år fremover)-0.78

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)97.98%
Driftsmargin (TTM)-43.44%
Fortjenestemargin (TTM)-42.49%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter154.84M
Netto fordringer56.14M
Samlede omløpsmidler521.55M
Goodwill0.00
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler602.49M
Leverandørgjeld10.01M
Kortsiktig/nåværende langsiktig gjeld63.00M
Sum kortsiktig gjeld116.57M
Sum gjeld176.81M
Aksjonærenes egenkapital425.69M
Netto varige driftsmidler425.69M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-113.30M
Kapitalutgifter (TTM)1.00K
Fri kontantstrøm (TTM)-113.30M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-51.06%
Avkastning på eiendeler-36.07%
Avkastning på investert kapital-49.97%
Kontantavkastning på investert kapital-26.05%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning19.54
Daglig høy20.11
Daglig lav19.53
Daglig volum1.21M
Tidenes høyeste57.00
1 år analytikerestimat18.47
Beta0.59
EPS (TTM)-1.34
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon27 Feb 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ACADS&P500
Nåværende prisfall fra toppnotering-65.21%-13.68%
Høyeste prisfall-96.29%-56.47%
Dato for høyeste fall12 Nov 20109 Mar 2009
Gj.snittlig fall fra topp-47.92%-11.49%
Gj.snittlig tid til ny topp51 days13 days
Maks tid til ny topp1820 days1805 days
SELSKAPSOPPLYSNINGER
ACAD (ACADIA Pharmaceuticals Inc) company logo
Markedsverdi
3.21B
Markedsverdi kategori
Mid-cap
Beskrivelse
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Ansatte
510
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Stephen R. Davis
Land
USA
By
San Diego
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
SAN DIEGO, January 09, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development (R&D). Dr. ...
9. januar 2023
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been...
3. januar 2023
SAN DIEGO, January 03, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in p...
3. januar 2023
Acadia Pharmaceuticals is working to develop novel RNA-based medicines for the treatment of severe and rare genetic diseases of the central nervous system. The On-Balance-Volume (OBV) line has weake...
3. januar 2023
SAN DIEGO, December 21, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00...
21. desember 2022
SAN DIEGO, November 08, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
8. november 2022
Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.
3. november 2022
Acadia (ACAD) delivered earnings and revenue surprises of 5.56% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2. november 2022
SAN DIEGO, November 02, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2022.
2. november 2022
Acadia Pharmaceuticals (ACAD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
1. november 2022
Neste side